Explore ADA’s 2023 updates on diabetes care, focusing on non-alcoholic fatty liver disease (NAFLD) and cirrhosis prevention. Learn from Dr. Kenneth Cusi on risk stratification, diagnostic tools like FIB-4, and latest management recommendations.
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Exploring the role of PPAR-y in the management of patients with Type 2 Diabetes and NAFLD with Prof. Kenneth Cusi (USA)
Discover the very special relationship between Non-alcoholic fatty liver disease (NAFLD) and Type 2 Diabetes (T2DM) with Prof Kenneth Cusi, USA. Each of these conditions seems to worsen the other.
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Prof Kenneth Cusi, USA, discusses the role of insulin sensitizers in NASH, and particularly how lifestyle interventions including weight loss can, in this context, be beneficial together with a pharmacological approach.
The liver meeting has been fantastic. There’s a lot of…
So the diabetologists are recognizing that they have to do…
That’s a very important concept because lipotoxicity is a driver…